The Phase 1 data are encouraging but early-stage; the key catalyst is the Phase 3 PRISM-MEL-301 trial readout. Monitor for enrollment updates and interim data. The stock may see modest positive movement on ASCO presentation buzz, but sustained upside depends on Phase 3 results.
Price Chart
Executive Summary
Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at ASCO 2026, showing a 6-month OS rate of 87% and DCR of 52% in 66 patients. The data support the 160 mcg dose selection for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma. While the results are clinically promising, the small sample size and early-stage nature limit immediate stock-moving impact.
Key Facts
- Brenetafusp monotherapy in 66 heavily pretreated advanced melanoma patients showed 6-month OS rate of 87% and median OS of 14.3 months.
- Disease control rate (DCR) was 52% and overall response rate (ORR) was 12%.
- Data support 160 mcg dose selection for Phase 3 PRISM-MEL-301 trial (brenetafusp + nivolumab vs. standard nivolumab regimens) in first-line advanced melanoma.
- Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance (median OS 14.7 months).
- Brenetafusp was generally well tolerated; most common TRAEs were CRS (56%), rash (44%), pyrexia (44%), and chills (38%), predominantly low grade.
- A second poster showed IL7 may enhance ImmTAC anti-tumor activity in vitro and in vivo.
Financial Impact
No financial data provided; early-stage clinical data with no revenue or guidance impact.
Risk Factors
- Phase 3 trial may fail to replicate Phase 1 efficacy in a larger, randomized setting.
- Competition from existing PD-1/CTLA-4 and LAG-3 therapies in first-line melanoma.
- Safety profile includes CRS and lymphopenia, which could limit tolerability in broader patient populations.
- Small sample size (n=66) limits statistical reliability of efficacy estimates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303917 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $32.46 $32.18 | ▼ −0.86% | ▼ −0.97% | $29.71 (−8.47%) |
Aug 6, 2026 8w ago | 8-K | $34.50 $34.20 | ▼ −0.87% | ▼ −2.08% | $29.71 (−13.88%) |
May 31, 2026 17w ago | Press Release | $29.13 $28.29 | ▼ −2.88% | ▼ −0.13% | $29.71 (+1.99%) |
Apr 19, 2026 23w ago | Press Release | $31.46 $28.56 | ▼ −9.22% | ▼ −10.13% | $29.71 (−5.56%) |
Apr 8, 2026 25w ago | 144 | $31.85 $31.64 | ▼ −0.66% | ▼ −4.18% | $29.71 (−6.72%) |
Mar 17, 2026 28w ago | Press Release | $30.04 $30.28 | ▲ +0.80% | ▲ +1.51% | $29.71 (−1.10%) |
Feb 25, 2026 31w ago | 8-K | $32.16 $33.73 | ▲ +4.88% | ▲ +5.98% | $29.71 (−7.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access